Doripenem is a carbapenem that has better in vitro potency against P.aeruginosa than meropenem does due to its activity against extended-spectrum beta-lactamase, which ultimately means that it could potentially be effective in clinical aspects. There have also been some positive results in a few phase 3 studies for telavancin, ceftobiprole, and cethromycin, despite their regulatory delays. On the other hand, a promising oral and intravenous aminomethylcycline PTK-0796, completed its phase 2 study versus linezolid for treatment of cSSSI. It was found to be similar to tigecycline’s spectrum, showing positive indications for MRSA, VRE, and Gram-negative pathogens, such as A. baumannii being present in its spectrum. Therefore, these results indicate that this drug could potentially be used in treating Gram-negative infections. There are also two anti-Gram positive oral drugs being tested; one is called iclaprim and the other is called RX-1741. Iclaprim behaves similarly to the drug trimethoprim and RX-1741 is a second-generation oxazolidinone. Another drug that has potential against Gram-negative infections, such as Acinetobacter species, is called BAL 30376 and is classified as a beta-lactam–beta-lactamase inhibitor. However, the drug telavancin is the only drug with a known novel mechanism of
Doripenem is a carbapenem that has better in vitro potency against P.aeruginosa than meropenem does due to its activity against extended-spectrum beta-lactamase, which ultimately means that it could potentially be effective in clinical aspects. There have also been some positive results in a few phase 3 studies for telavancin, ceftobiprole, and cethromycin, despite their regulatory delays. On the other hand, a promising oral and intravenous aminomethylcycline PTK-0796, completed its phase 2 study versus linezolid for treatment of cSSSI. It was found to be similar to tigecycline’s spectrum, showing positive indications for MRSA, VRE, and Gram-negative pathogens, such as A. baumannii being present in its spectrum. Therefore, these results indicate that this drug could potentially be used in treating Gram-negative infections. There are also two anti-Gram positive oral drugs being tested; one is called iclaprim and the other is called RX-1741. Iclaprim behaves similarly to the drug trimethoprim and RX-1741 is a second-generation oxazolidinone. Another drug that has potential against Gram-negative infections, such as Acinetobacter species, is called BAL 30376 and is classified as a beta-lactam–beta-lactamase inhibitor. However, the drug telavancin is the only drug with a known novel mechanism of